BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Acalabrutinib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Acalabrutinib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05065554-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05065554)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: ACALA-R In Predominantly Demye
 linating IgM Mediated Neuropathy\nEstimated primary completion: 1 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0506
 5554
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04462328-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 1 readout est. (NCT04462328)
DESCRIPTION:Acalabrutinib\, phase 1.\nStudy: Acalabrutinib and Durvalumab i
 n Primary and Secondary Central Nervous System Lymphoma\nEstimated primary
  completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04462328
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05971251-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 1 readout est. (NCT05971251)
DESCRIPTION:Acalabrutinib\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy:
  Addition of Loncastuximab Tesirine to Acalbrutinib \, Chronic Lymphocytic
  Leukemia\nEstimated primary completion: 31 December 2026. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05971251
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06757647-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06757647)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lym
 phocytic Lymphoma\nEstimated primary completion: 31 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06757647
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04115631-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04115631)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Compa
 rison of Three Chemotherapy Regimens for the Treatment of Patients With Ne
 wly Diagnosed Mantle Cell Lymphoma\nEstimated primary completion: 31 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutin
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4115631
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05214183-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05214183)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lympho
 ma\nEstimated primary completion: January 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT05214183
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05943496-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Acalabrutinib: Phase 1 readout est. (NCT05943496)
DESCRIPTION:Acalabrutinib\, phase 1\, Chronic Lymphocytic Leukemia.\nStudy:
  Tafasitamab\, Acalabrutinib\, and Obinutuzumab for the Treatment of Previ
 ously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphom
 a\nEstimated primary completion: 1 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05943496
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04978584-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270116
DTEND;VALUE=DATE:20270117
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04978584)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Rituximab\, Lenalidomide\, Acalabrutinib\, Tafasitamab Alone and With Co
 mbination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal C
 enter Diffuse Large B-Cell Lymphoma\, Smart Stop Study\nEstimated primary 
 completion: 16 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04978584
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05256641-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT05256641)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStu
 dy: Acalabrutinib Maintenance for the Treatment of Patients With Large B-c
 ell Lymphoma\nEstimated primary completion: 31 January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05256641
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04722172-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04722172)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinu
 tuzumab in People With CLL or SLL\nEstimated primary completion: February 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04722
 172
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923162-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Acalabrutinib: Phase 4 readout est. (NCT07923162)
DESCRIPTION:Acalabrutinib\, phase 4.\nStudy: MACE and BTK Inhibitors\nEstim
 ated primary completion: 1 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07923162
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02972840-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT02972840)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: A Study of BR Alone Versus in 
 Combination With Acalabrutinib in Subjects With Previously Untreated MCL\n
 Estimated primary completion: 15 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT02972840
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04529772-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270222
DTEND;VALUE=DATE:20270223
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT04529772)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : A Combination of Acalabrutinib With R-CHOP in Subjects With Previously U
 ntreated Non-GCB DLBCL (ACE-LY-312)\nEstimated primary completion: 22 Febr
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabruti
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04529772
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04484012-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04484012)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Modifie
 d Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of R
 elapsed or Refractory Mantle Cell Lymphoma\nEstimated primary completion: 
 23 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/aca
 labrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT04484012
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05495464-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Acalabrutinib: Phase 1 readout est. (NCT05495464)
DESCRIPTION:Acalabrutinib\, phase 1\, Mantle Cell Lymphoma.\nStudy: A Pilot
  "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtage
 ne Autoleucel Therapy in Patients With Previously Untreated High-risk Mant
 le Cell Lymphoma\nEstimated primary completion: 31 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05495464
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03836261-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT03836261)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199)
 \, With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Pre
 viously Untreated CLL\nEstimated primary completion: 30 April 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT03836261
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03128879-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03128879)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL\nEs
 timated primary completion: 31 May 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03128879
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04855695-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT04855695)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: Avo I
 n R/R And Previously Untreated MCL\nEstimated primary completion: 30 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04855
 695
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04189757-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04189757)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma\nEst
 imated primary completion: 30 June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT04189757
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04505254-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04505254)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic L
 eukemia\nEstimated primary completion: 30 June 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04505254
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054776-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270713
DTEND;VALUE=DATE:20270714
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06054776)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib\, Obinutuzumab\, and Glofitamab for the Treatment of Relapsed or Re
 fractory Mantle Cell Lymphoma\nEstimated primary completion: 13 July 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06054776
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05057494-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05057494)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzu
 mab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocy
 tic Lymphoma\nEstimated primary completion: 15 July 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05057494
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319456-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT06319456)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: A Study of Lisaftoclax (APG-25
 75) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagno
 sed CLL/SLL.\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06319456
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04941716-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04941716)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib in Combination With Venetoclax for the Treatment of Refract
 ory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
 a\, The AVENUE-2 Trial\nEstimated primary completion: 10 August 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04941716
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04646395-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04646395)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: Study of Acalabrutinib and Taf
 asitamab in MZL Patients\nEstimated primary completion: 15 September 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04646395
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03571568-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT03571568)
DESCRIPTION:Acalabrutinib\, phase 1/2.\nStudy: A Study of BI-1206 in Combin
 ation With Rituximab With or Without Acalabrutinib in Subjects With Indole
 nt B-Cell NHL\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03571568
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04002947-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04002947)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffus
 e Large B-cell Lymphoma\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04002947
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546620-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04546620)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffus
 e Large B-cell Lymphoma (DLBCL)\nEstimated primary completion: November 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0454662
 0
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06958705-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06958705)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Mo
 notherapy\nEstimated primary completion: 1 December 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06958705
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06441097-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06441097)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT06441097
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07029737-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07029737)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  to Evaluate Acalabrutinib\, in Combination With the R-CHOP Standard of Ca
 re\, for Previously Untreated Mantle Cell Lymphoma in Spain\nEstimated pri
 mary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07029737
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03946878-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280208
DTEND;VALUE=DATE:20280209
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03946878)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Venetoc
 lax and Acalabrutinib in Treating Patients With Relapsed or Refractory Man
 tle Cell Lymphoma\nEstimated primary completion: 8 February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT03946878
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Parti
 cipants Receiving Oral Venetoclax in Combination With Intravenously Infuse
 d Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymp
 hocytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04560322-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04560322)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL\nEstimated primary c
 ompletion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/acalabrutinib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT04560322
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04404088-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04404088)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: Acalabrutinib\, Lenalidomide\,
  and Rituximab for the Treatment of CD20 Positive Stage III-IV\, Grade 1-3
 a Follicular Lymphoma\nEstimated primary completion: 1 March 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT04404088
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05197192-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05197192)
DESCRIPTION:Acalabrutinib\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy:
  A Phase-3-trial of Acalabrutinib\, Obinutuzumab & Venetoclax Compared to 
 Obinutuzumab and Venetoclax in Previously Untreated Patients With High Ris
 k CLL\nEstimated primary completion: May 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05197192
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07014917-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07014917)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL\
 nEstimated primary completion: 5 June 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07014917
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899337-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03899337)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: A Trial of CHOP-R Therapy\, Wi
 th or Without Acalabrutinib\, in Patients With Newly Diagnosed Richter's S
 yndrome\nEstimated primary completion: 30 June 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03899337
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169737-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280709
DTEND;VALUE=DATE:20280710
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04169737)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the T
 reatment of High Risk\, Recurrent\, or Refractory Chronic Lymphocytic Leuk
 emia or Small Lymphocytic Lymphoma\nEstimated primary completion: 9 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT041697
 37
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04765111-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280830
DTEND;VALUE=DATE:20280831
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04765111)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib and Rituximab for the Treatment of Previously Untreated Mantle Cell
  Lymphoma\nEstimated primary completion: 30 August 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04765111
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566887-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04566887)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma\nEstimated
  primary completion: September 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04566887
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05951959-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05951959)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: A Study
  of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treat
 ment Naïve Mantle Cell Lymphoma\nEstimated primary completion: 31 October
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0595
 1959
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03516617-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281111
DTEND;VALUE=DATE:20281112
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT03516617)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Acalabrutinib With or Without Obinutuzumab in Treating Patients With Earl
 y-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma\nEstima
 ted primary completion: 11 November 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03516617
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07257055-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281124
DTEND;VALUE=DATE:20281125
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07257055)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: Phase 2 Study of BTKi-Rituxima
 b Induction Followed by Glofitamab Consolidation in High Risk Untreated MC
 L Patients - WINDOW-4 Study\nEstimated primary completion: 24 November 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07257055
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04523428-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04523428)
DESCRIPTION:Acalabrutinib\, phase 2.\nStudy: REtreatment With VEnetoclax an
 d Acalabrutinib After Venetoclax Limited Duration (REVEAL)\nEstimated prim
 ary completion: December 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/acalabrutinib#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04523428
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07052695-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT07052695)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Chronic Lymphocytic Leukemia.\nStud
 y: Mosunetuzumab for CLL MRD Clearance\nEstimated primary completion: 31 D
 ecember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabr
 utinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07052695
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07635511-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT07635511)
DESCRIPTION:Acalabrutinib\, phase 3.\nStudy: Acalabrutinib Maleate and Bort
 ezomib for Patients With HLA Antibodies\nEstimated primary completion: 1 J
 anuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07635511
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04604067-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT04604067)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Mult
 icenter\, Open-label\, Phase II Trial.\nEstimated primary completion: 30 J
 anuary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04604067
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05820841-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Acalabrutinib: Phase 3 readout est. (NCT05820841)
DESCRIPTION:Acalabrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untrea
 ted Diffuse Large B-Cell Lymphoma\nEstimated primary completion: February 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05820
 841
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07582159-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290414
DTEND;VALUE=DATE:20290415
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07582159)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chroni
 c Lymphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary compl
 etion: 14 April 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /acalabrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07582159
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05952024-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290422
DTEND;VALUE=DATE:20290423
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT05952024)
DESCRIPTION:Acalabrutinib\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail P
 atients With DLBCL\nEstimated primary completion: 22 April 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05952024
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024706-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07024706)
DESCRIPTION:Acalabrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy:
  MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Rel
 apsed After a Course of BTKi + BCL2i Combination\, With or Without Obinutu
 zumab\nEstimated primary completion: 1 May 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07024706
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03868722-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Acalabrutinib: Phase 2/3 readout est. (NCT03868722)
DESCRIPTION:Acalabrutinib\, phase 2/3.\nStudy: Acalabrutinib and Venetoclax
  Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection 
 or Early Treatment\nEstimated primary completion: 31 July 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03868722
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564038-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20300520
DTEND;VALUE=DATE:20300521
SUMMARY:Acalabrutinib: Phase 1/2 readout est. (NCT06564038)
DESCRIPTION:Acalabrutinib\, phase 1/2\, Mantle Cell Lymphoma.\nStudy: A Stu
 dy of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents 
 for Mature B-Cell Malignancies\nEstimated primary completion: 20 May 2030.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06564038
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06651970-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20320930
DTEND;VALUE=DATE:20321001
SUMMARY:Acalabrutinib: Phase 4 readout est. (NCT06651970)
DESCRIPTION:Acalabrutinib\, phase 4.\nStudy: Acalabrutinib Monotherapy vs I
 nvestigator's Choice of Treatment in Patients With CL Leukaemia and Heart 
 Failure\nEstimated primary completion: 30 September 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/acalabrutinib#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06651970
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07910435-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20330101
DTEND;VALUE=DATE:20330102
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT07910435)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Polatuz
 umab Vedotin\, Mosunetuzumab\, and Acalabrutinib for the Treatment of Mant
 le Cell Lymphoma\, PAcMan Trial\nEstimated primary completion: 1 January 2
 033. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/acalabrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079104
 35
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846489-3339@assetmemo.bio
DTSTAMP:20261121T004119Z
DTSTART;VALUE=DATE:20330210
DTEND;VALUE=DATE:20330211
SUMMARY:Acalabrutinib: Phase 2 readout est. (NCT06846489)
DESCRIPTION:Acalabrutinib\, phase 2\, Mantle Cell Lymphoma.\nStudy: Acalabr
 utinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate
 -Risk Younger Untreated Mantle Cell Lymphoma\nEstimated primary completion
 : 10 February 2033. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/a
 calabrutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06846489
URL:https://assetmemo.bio/drug/acalabrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
